丹红注射液联合依诺肝素钠治疗急性ST段抬高型心肌梗死的临床研究

目的探讨丹红注射液联合依诺肝素钠注射液治疗急性ST段抬高型心肌梗死的临床疗效。方法选取2015年6月—2016年6月天津中医药大学第一附属医院收治的急性ST段抬高型心肌梗死患者96例为研究对象,所有患者随机分为对照组和治疗组,每组各48例。对照组于溶栓后12 h肌内注射依诺肝素钠注射液,7 500 IU/次,1次/d。治疗组在对照组的基础上静脉滴注丹红注射液,30 m L加入到5%葡萄糖注射液250 m L中,1次/d。两组均连续治疗7 d。观察两组的临床疗效,比较两组的血清学指标和心血管事件发生情况。结果治疗后,对照组和治疗组的总有效率分别为72.9%、91.7%,两组比较差异具有统计学意义(P0.05)。治疗后,两组血清高敏C-反应蛋白(hs-CRP)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、肌钙蛋白T(c Tn T)水平均显著降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些血清学指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。对照组和治疗组院内心血管事件发生率分别为8.4%、4.2%,院外心血管事件发生率分别为10.4%、4.2%,两组比较差异无统计学意义。结论丹红注射液联合依诺肝素钠注射液治疗急性ST段抬高型心肌梗死具有较好的临床疗效,能降低血清hs-CRP、CK、CK-MB、c Tn T水平,安全性较好,具有一定的临床推广应用价值。

Clinical study on Danhong Injection combined with enoxaparin sodium in treatment of acute ST segment elevation myocardial infarction

Objective To investigate the clinical efficacy of Danhong Injection combined with Enoxaparin Sodium Injection in treatment of acute ST segment elevation myocardial infarction. Methods Patients (96 cases) with acute ST segment elevation myocardial infarction in the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from June 2015 to June 2016 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were im administered with Enoxaparin Sodium Injection after thrombolytic therapy for 12 h, 7 500 IU/time, once daily. Patients in the treatment group were iv administered with Danhong Injection on the basis of the control group, 30 mL added into 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, and serological indexes and cardiovascular event in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 72.9% and 91.7%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of serum hs-CRP, CK, CK-MB, and cTnT in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the serological indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the hospital cardiovascular event rates in the control and treatment groups were 8.4% and 4.2%, respectively, the outside hospital cardiovascular event rates in the control and treatment groups were 10.4% and 4.2%, respectively, and there was no difference between two groups. Conclusion Danhong Injection combined with Enoxaparin Sodium Injection has clinical curative effect in treatment of acute ST segment elevation myocardial infarction, can decrease the levels of serum hs-CRP, CK, CK-MB, and cTnT, with good safety, which has a certain clinical application value.